Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR...
This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...
Some of the best links we picked up around the internet
2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...
In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...
In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.
In this week’s clinical update, we take a look at a CRISPR-engineered T cell receptor-T cell therapy that is designed to treat all genetic subtypes of...
This week, we look at a CRISPR-based therapy for HIV that has just passed the IND approval stage, and will soon be tested in a Phase 1/2 clinical...
